NASDAQ · AQST

Aquestive Therapeutics, Inc.

$3.68 -$0.09 (-2.39%) 1D After hours

Key Metrics

$461.72M
Market cap
P/E · TTM
$50.27M
Revenue · TTM
−$68.91M
Net income
EPS · TTM $-0.72
Dividend yield
Free cash flow −$44.32M
Beta · 1Y 1.16
EBITDA · TTM −$68.39M
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 24
    From its Jun 23 high, the share price fell 27%.

    Peak close $5.03 on Jun 23; trough close $3.68 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -27%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 14
    The stock moved +14.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 14
  • Feb 2
    The stock moved +39.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 2

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$461.72M
Enterprise value$395.98M
Shares outstanding125.5M
52-wk range$2.93 – $7.55
Avg volume · 20D1.3M
Net cash $65.73M
Book value / share$-0.36
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Aquestive Therapeutics, Inc.
IPO dateJul 25, 2018
Employees147

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S9.18
P/FCF
EV/EBITDA
EV/Sales7.88
Graham №

Profitability

Gross
Operating -137.1%
Net -137.1%
FCF -88.2%
ROE / ROIC 146.3% · 69.1%

Financial Health

Current ratio4.10
Quick ratio3.85
Debt / equity-1.32
Debt / EBITDA -0.66
Net cash $65.73M
Working capital$98.43M

Cash Flow · TTM

Operating CF −$43.84M
Capex −$479.00K
Free cash flow −$44.32M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

-3.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings